Determining the Optimal Use of Antibiotics in Hematopoietic Stem Cell Transplant Recipients
Bibliographic record
Abstract
This study by Rashidi and colleagues 1 sought to characterize the association of antibiotic exposure and timing of the exposure relative to allogeneic hematopoietic stem cell transplantation (allo-HCT) with the hazard of developing acute graft-vs-host disease (aGVHD), which is one of the most common complications of allo-HCT.Rashidi et al 1 applied 3 orthogonal methods (conventional Cox proportional-hazards regression, marginal structural models, and machine learning) to analyze data collected from 2023 patients who underwent their first T-replete allo-HCT at a single center between 2010 and 2021.Each of the included analytical methods has its own strengths and weaknesses, but together they provided a comprehensive perspective.Rashidi et al 1 reported that weeks 1 and 2 after allo-HCT were the highest-risk intervals, with several antibiotic exposures associated with higher risk of subsequent aGVHD.Of note, carbapenems exposure weeks 1 and 2 after allo-HCT was associated with a minimum hazard ratio (HR) of 2.75 (95% CI, 1.77-4.28),whereas week 1 after allo-HCT exposure to penicillins with β-lactamase inhibitors was associated with a minimum HR of 6.55 (95% CI, 2.35-18.20).Across all 3 methods, the data from the study by Rashidi et al 1 also suggest that pre-allo-HCT exposure to penicillins with β-lactamase inhibitors was associated with a lower risk of aGVHD.These findings have implications on patient care, as penicillins with β-lactamase inhibitor (eg, piperacillin-tazobactam) and carbapenems (eg, meropenem) are broad-spectrum antibiotics with antipseudomonal activity commonly administered during pre-engraftment, when the patient is most at risk of infections due to profound and prolonged neutropenia.Although there was some variability in the results among the 3 analytical methods, taken together, they suggest that a thoughtful and judicious approach to antibiotic prescribing during the critical periods during and immediately after allo-HCT is warranted to mitigate against aGVHD.In addition to the significant morbidity affecting the skin, gastrointestinal tract, and liver, treatment for aGVHD commonly involves escalating the dose of immunosuppression plus systemic corticosteroids.In turn, these interventions create additional risks for infections and perpetuate the cycle for more antimicrobials.Determining the optimal use of antibiotics is a topic of interest to both allo-HCT clinicians and the antimicrobial stewardship team.In the past decade, cancer therapy underwent dramatic advances through the discovery of targeted small-molecule therapies, novel application of stem cell transplant techniques, and the emerging use of cellular therapy, such as chimeric antigen receptor T-cell therapy.However, infectious complications and antimicrobial resistance continue to pose significant threats to clinical success. 2 Compared with cancer treatment, the antimicrobial pipeline has made modest progress in the availability of new classes of antibiotics, although not nearly as prolific.Thus, preserving the effectiveness of antibiotics and mitigating against antibiotic resistance remain integral to supporting patients throughout their cancer treatment.Antimicrobial stewardship interventions for the prevention and management of neutropenic fever in patients receiving treatment for hematological malignant neoplasms is gaining momentum.3 For patients undergoing allo-HCT, the role of antibiotics, regimen selection, and timing of antibiotic administration during the peritransplant periods (ie, pretransplant conditioning regimen and pre-engraftment after HCT) is less well understood.Furthermore, there is a lack of consensus framework to assess the likelihood of benefit vs the potential harms from antibiotic exposure in the immediate, medium, and long term after allo-HCT, making implementation of antimicrobial stewardship more challenging.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.001 | 0.012 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.000 |
| Bibliometrics | 0.001 | 0.000 |
| Science and technology studies | 0.001 | 0.001 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.001 | 0.000 |
| Research integrity | 0.005 | 0.006 |
| Insufficient payload (model declined to judge) | 0.002 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".